Prospective Determination of Plasma Imipenem Concentrations in Critically Ill Children-Reference-Cited by-同舟云学术

Prospective Determination of Plasma Imipenem Concentrations in Critically Ill Children

Published:2006-07 Issue:7 Volume:50 Page:2563-2568
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Giannoni Eric¹,Moreillon Philippe²,Cotting Jacques¹,Moessinger Adrien¹,Bille Jacques³,Décosterd Laurent⁴,Zanetti Giorgio⁵,Majcherczyk Paul²,Bugnon Denis⁶

Affiliation:

1. Department of Pediatrics, CHUV, CH-1011 Lausanne, Switzerland

2. Department of Fundamental Microbiology, University of Lausanne, Biophore Building, CH-1015 Lausanne, Switzerland

3. Institute of Microbiology, CHUV, CH-1011 Lausanne, Switzerland

4. Division of Clinical Pharmacology, CHUV, CH-1011 Lausanne, Switzerland

5. Department of Hospital Hygiene, CHUV, CH-1011 Lausanne, Switzerland

6. Laboratoire d'Antibiologie (UPRES EA-1156), Medicine School, F-44035 Nantes Cedex 01, France

Abstract

ABSTRACT Plasma imipenem concentrations were measured in 19 critically ill children (median age, 0.8 year; range, 0.02 to 12.9 years). Wide interindividual variations (2 to 4× at peak and >10× at trough concentrations) resulted in unpredictable plasma levels in several children. To avoid subtherapeutic drug levels, we recommend treatment with at least 100 mg/kg of body weight/day of imipenem-cilastatin for critically ill children requiring such therapy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01149-05

Reference25 articles.

1. Begue, P. C., S. Baron, P. Challier, J. L. Fontaine, and G. Lasfargues. 1987. Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates. Scand. J. Infect. Dis.52(Suppl.):40-45.

2. Belzberg, H., J. Zhu, E. E. Cornwell III, J. A. Murray, J. Sava, A. Salim, G. C. Velmahos, and M. A. Gill. 2004. Imipenem levels are not predictable in the critically ill patient. J. Trauma56:111-117.

3. Besunder, J. B., M. D. Reed, and J. L. Blumer. 1988. Principles of drug biodisposition in the neonate. I. A critical evaluation of the pharmacokinetic-pharmacodynamic interface. Clin. Pharmacokinet.14:189-216.

4. Blumer, J. L. 1996. Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr. Infect. Dis. J.15:733-737.

5. Pitfalls in Cefepime Titration from Human Plasma: Plasma- and Temperature-Related Drug Degradation In Vitro

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review;Frontiers in Pharmacology;2022-09-21

2. Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation;Journal of Antimicrobial Chemotherapy;2021-11-17

3. Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine;Antibiotics;2021-09-28

4. Validation and clinical application of a multiplex high performance liquid chromatography – tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections;Journal of Chromatography B;2020-11

5. Dosing Recommendations for Pediatric Patients With Renal Impairment;The Journal of Clinical Pharmacology;2020-06-15